Related Experiment Video
Updated: Apr 22, 2026

In Vivo Evaluation of the Mechanical and Viscoelastic Properties of the Rat Tongue
Published on: July 6, 2017
Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study : A Randomized Controlled
Atul Malhotra1, Alan R Schwartz2, Eric Lovett3
1Pulmonary, Critical Care, Sleep Medicine and Physiology, Department of Medicine, University of California San Diego, La Jolla, California (A.M.).
Proximal hypoglossal nerve stimulation (pHGNS) effectively treats moderate-to-severe obstructive sleep apnea (OSA) in patients intolerant to positive airway pressure therapy. This study showed significant improvements in apnea-hypopnea index and patient-reported outcomes with pHGNS compared to control.
Area of Science:
- Medical Devices
- Sleep Medicine
- Neuromodulation
Background:
- Obstructive sleep apnea (OSA) affects millions, with limited treatment options for those unable to tolerate positive airway pressure (PAP) therapy.
- Hypoglossal nerve stimulation (HGNS) offers an alternative, with proximal HGNS (pHGNS) presenting potential advantages in electrode placement and stimulation.
- This study investigates the efficacy and safety of pHGNS in moderate-to-severe OSA patients.
Purpose of the Study:
- To evaluate the effectiveness of proximal hypoglossal nerve stimulation (pHGNS) in treating moderate-to-severe obstructive sleep apnea (OSA).
- To assess the safety profile of pHGNS in this patient population.
- To compare pHGNS outcomes against a control group in patients with OSA.
Main Methods:
- A 7-month randomized controlled trial followed by a 6-month open-label extension involving 104 adult patients with moderate-to-severe OSA across 23 U.S. health centers.
- Patients received pHGNS implantation and were randomized 2:1 to receive therapy starting at month 1 or month 7 (control).
- Primary endpoint: proportion of patients achieving >50% AHI reduction and AHI < 20 events/h at 7 months. Secondary endpoints included oxygen desaturation index (ODI) and Epworth Sleepiness Scale (ESS) improvements.
Main Results:
- At 7 months, 58.2% of the pHGNS treatment group achieved the primary endpoint versus 13.5% in the control group.
- The treatment group showed significant improvements in ODI (68.7% vs. 37.8%) and median ESS scores (10.0 to 6.0) compared to the control group.
- No serious procedure-related adverse events were reported, indicating a favorable safety profile for pHGNS.
Conclusions:
- Proximal hypoglossal nerve stimulation (pHGNS) demonstrated clinically significant efficacy in improving OSA parameters and patient-reported outcomes compared to control.
- pHGNS represents a viable therapeutic option for patients with moderate-to-severe OSA, particularly those who cannot tolerate positive airway pressure therapy.
- Further research with larger sample sizes and longer follow-up is warranted to fully elucidate the long-term benefits and safety of pHGNS.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Suctioning the Oropharyngeal Airway
After assembling the equipment, the nurse should practice hand hygiene and don appropriate PPE according to infection control guidelines to avoid the...
Hyperpnea and Hyperventilation

